Silence Therapeutics PLC Silence Therapeutics Announces Board Change (3512W)
16 April 2019 - 8:00PM
UK Regulatory
TIDMSLN
RNS Number : 3512W
Silence Therapeutics PLC
16 April 2019
Silence Therapeutics Announces Board Change
April 16, 2019
LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the
Company") a leader in the discovery, development and delivery of
novel RNA therapeutics for the treatment of serious diseases,
announces today that Dr. Andy Richards, CBE, is leaving his role as
interim non-executive Chair and a Director of the Company with
immediate effect. The Company's previously announced process to
appoint a new Chair is ongoing.
Dr. David Horn Solomon, Chief Executive Officer, commented:
"Andy Richards has served on the Board of Silence since 2016, first
as a non-executive director and more recently as interim Chairman.
During this time, Andy has been instrumental in a implementing a
bold turnaround of Company strategy which has re-energised our
drug-development programmes and led us to a point where we are now
preparing to commence in-human trials with our lead RNAi candidate
SLN124. I would like to thank Andy for his invaluable contribution
to the Company and wish him well in his future endeavours."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20 3457
Dr David Horn Solomon, Chief Executive 6900
Officer
Dr Rob Quinn, Interim Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0)20 7418
James Steel/Oliver Jackson 8900
European IR Tel: +44 (0) 20
Consilium Strategic Communications 3709 5700
Mary-Jane Elliott/Angela Gray
silencetherapeutics@consilium-comms.com
US IR Tel: +1 (443) 213-0505
Westwicke Partners
Peter Vozzo
Peter.vozzo@westwicke.com
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural
mechanism of RNA interference, or RNAi, within its cells. Its
proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using
its enabling delivery systems, it has achieved an additional
level of specificity by delivering its
therapeutic RNA molecules exclusively to target cells. Silence's
proprietary RNA chemistries and
delivery systems are designed to improve the stability of our
molecules and enhance effective delivery
to target cells, providing a powerful modular technology well
suited to tackle life-threatening diseases.
For more information, please visit:
https://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALIFVASTIRLIA
(END) Dow Jones Newswires
April 16, 2019 06:00 ET (10:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024